Supporting research to better understand pancreatic cancer with the goal of improving outcomes for patients.

Each year, more than 350,000 people worldwide are diagnosed with pancreatic cancer – one of the deadliest cancers – with the majority of cases diagnosed in late stage. Despite advances in therapy over the past two decades that have led to doubled 5-year survival rates, pancreatic cancer 5-year survival is still only in the single digits – 8% – due to the complex nature of the disease and lack of symptoms until the disease has progressed.
?
Celgene is committed to better understanding pancreatic cancer with the goal of improving outcomes for patients. As a leader focused on helping patients with particularly challenging cancers with limited treatment options, we remain committed to delivering new and better options for these patients through our deep scientific expertise.

Pancreatic Cancer Caregivers Need to Take Time for Themselves

Caregivers must take care of themselves to effectively care for their loved ones.

Family History Helped This Survivor Catch Pancreatic Cancer Early

About 10 percent of pancreatic cancer cases are connected to family history.

At the Forefront of the Fight Against Pancreatic Cancer

At this year’s ASCO meeting, data will highlight progress in pancreatic cancer research.